Heparin-induced thrombocytopenia future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]

Overview

Future therapies involve use of factor X inhibitors or direct thrombin inhibitors. The data is currently not mature enough to make any clinical recommendations.

Future or Investigational Therapies

Future therapies for HIT focus on use of new oral anticoagulants.^[1] Director factor X inhibitors and newer direct thrombin inhibitors are being studied, but the data is currently in its infancy. Cost-effectiveness analyses will need to be done to determine whether it is appropriate to use these new agents.

References

↑ Harenberg J, Marx S, Krejczy M, Wehling M (2012). “New anticoagulants – promising and failed developments”. Br J Pharmacol. 165 (2): 363–72. doi:10.1111/j.1476-5381.2011.01578.x. PMC 3268190. PMID 21740405.

[pmid21740405-1] Harenberg J, Marx S, Krejczy M, Wehling M (2012). “New anticoagulants – promising and failed developments”. Br J Pharmacol. 165 (2): 363–72. doi:10.1111/j.1476-5381.2011.01578.x. PMC 3268190. PMID 21740405.

[1]